Fig. 2: Guidance for switching to faricimab in previously treated nAMD. | Eye

Fig. 2: Guidance for switching to faricimab in previously treated nAMD.

From: Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialists

Fig. 2

aSuboptimal response defined as intraretinal fluid or subretinal fluid on OCT, other anatomic features of active or worsening disease (e.g. new haemorrhage OR new SHRM), or unchanged (≤5-letter improvement)/reduced VA due to nAMD, after three consecutive monthly intravitreal injections. bTreatment-resistant nAMD generally defined as persistent retinal fluid on OCT despite continued intravitreal anti-VEGF injections over a 12-month period. cPrimarily maintained at this treatment interval or later shortened. dIn patients previously anti-VEGF-treated at maximum Q4W intervals, initial loading with monthly injections may continue to improve anatomic features. nAMD neovascular age-related macular degeneration, OCT optical coherence tomography, Q4W–Q7W every 4–7 weeks, Q8W every 8 weeks, Q10W–Q12W every 10–12 weeks, Q16W every 16 weeks, SHRM subretinal hyperreflective material, T&E treat-and-extend, VA visual acuity.

Back to article page